Zolgensma market forecast points to growth through 2035

9 hours ago
Zolgensma market forecast points to growth through 2035
By AI, Created 17:15 UTC, Nov 20, 2026, AGP -

The Business Research Company says the global Zolgensma market is set to expand through 2035 as newborn screening, rare disease diagnosis and gene therapy investment rise. North America led the market in 2025, while Asia-Pacific is positioned for stronger growth ahead.

Why it matters: - Zolgensma sits at the center of a fast-moving gene therapy market for spinal muscular atrophy, a rare disease that can cause severe muscle weakness and life-threatening complications in infants and young children. - The market outlook matters because broader newborn screening, earlier diagnosis and higher healthcare spending can increase access to one-time curative treatments. - The report projects demand for gene therapies will keep rising as health systems weigh long-term outcomes against high upfront treatment costs.

What happened: - The Business Research Company released a Zolgensma market report for 2026 with forecasts running through 2035. - The report says the market has expanded on the back of better gene therapy delivery methods, clinical success in SMA type 1, newborn screening and regulatory support. - North America was the largest Zolgensma market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company offers a free sample of the report and the full market report.

The details: - Zolgensma is a gene therapy for spinal muscular atrophy. - The treatment replaces the defective or missing SMN1 gene in children younger than two years old. - The therapy aims to restore motor function and improve survival. - Rising SMA prevalence is a major growth driver for the market. - NICE estimated in August 2025 that SMA affects about 1 in 14,000 births globally. - NICE also estimated about 47 infants were diagnosed in the UK in 2023. - The report says over 6,000 rare diseases exist and collectively affect up to 36 million people in the EU, based on a September 2024 report from a Netherlands-based international organization in the European Union. - Higher healthcare expenditure is supporting adoption of costly gene therapies. - US health care spending rose 7.5% in 2023 to $4.9 trillion, or about $14,570 per person, according to the Centers for Medicare & Medicaid Services.

Between the lines: - The market is shifting toward earlier intervention, wider use of viral vector platforms and broader acceptance of one-time gene therapies. - Growth in newborn screening is likely to keep identifying patients earlier, which can expand treatment eligibility for Zolgensma. - Asia-Pacific is expected to post notable growth as awareness rises and healthcare infrastructure improves. - The report frames long-term economic value as a key part of the case for gene therapies, not just clinical benefit.

What's next: - The report expects more investment in gene therapy research pipelines and viral vector manufacturing. - Wider newborn screening programs should continue to increase diagnosed SMA cases. - Demand should rise for curative rare disease treatments as healthcare systems expand access and reimbursement. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspots infographics and updated trend analysis.

The bottom line: - Zolgensma's market story is no longer just about a single therapy; it reflects a broader shift toward early, one-time gene treatments for rare diseases with long-term health and economic value.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Economic News Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Economic News Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.